Stock Research for BIOAF

BIOAF

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

BIOAF Stock Chart & Research Data

The BIOAF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BIOAF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


BIOAF Due diligence Resources & Stock Charts

The BIOAF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BIOAF Detailed Price Forecast - CNN Money CNN View BIOAF Detailed Summary - Google Finance
Yahoo View BIOAF Detailed Summary - Yahoo! Finance Zacks View BIOAF Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View BIOAF Trends & Analysis - Trade-Ideas Barrons View BIOAF Major Holders - Barrons
NASDAQ View BIOAF Call Transcripts - NASDAQ Seeking View BIOAF Breaking News & Analysis - Seeking Alpha
Spotlight View BIOAF Annual Report - CompanySpotlight.com OTC Report View BIOAF OTC Short Report - OTCShortReport.com
TradeKing View BIOAF Fundamentals - TradeKing Charts View BIOAF SEC Filings - Bar Chart
WSJ View Historical Prices for BIOAF - The WSJ Morningstar View Performance/Total Return for BIOAF - Morningstar
MarketWatch View the Analyst Estimates for BIOAF - MarketWatch CNBC View the Earnings History for BIOAF - CNBC
StockMarketWatch View the BIOAF Earnings - StockMarketWatch MacroAxis View BIOAF Buy or Sell Recommendations - MacroAxis
Bullish View the BIOAF Bullish Patterns - American Bulls Short Pains View BIOAF Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View BIOAF Stock Mentions - StockTwits PennyStocks View BIOAF Stock Mentions - PennyStockTweets
Twitter View BIOAF Stock Mentions - Twitter Invest Hub View BIOAF Investment Forum News - Investor Hub
Yahoo View BIOAF Stock Mentions - Yahoo! Message Board Seeking Alpha View BIOAF Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for BIOAF - SECform4.com Insider Cow View Insider Transactions for BIOAF - Insider Cow
CNBC View BIOAF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BIOAF - OTC Markets
Yahoo View Insider Transactions for BIOAF - Yahoo! Finance NASDAQ View Institutional Holdings for BIOAF - NASDAQ


Stock Charts

FinViz View BIOAF Stock Insight & Charts - FinViz.com StockCharts View BIOAF Investment Charts - StockCharts.com
BarChart View BIOAF Stock Overview & Charts - BarChart Trading View View BIOAF User Generated Charts - Trading View




Latest Financial News for BIOAF


Bioasis to Present at Investor & Industry Conferences in January 2019
Posted on Thursday December 13, 2018

Bioasis Technologies Inc.  , a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform t


Bioasis Appoints Dr. Deborah A. Rathjen as Executive Chair of the Board of Directors
Posted on Monday December 10, 2018

OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the appointment of Deborah A. Rathjen, B.Sc.


Bioasis Announces Voting Results for 2018 Annual and Special Meeting
Posted on Monday November 26, 2018

OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the voting results from its Annual & Special Meeting held on Mon., Nov. 26, 2018 in Toronto, Ontario. All five (5) candidates nominated for election to the Bioasis board of directors and listed in the Company's Management Information Circular dated Oct. 25, 2018, being Deborah Ann Rathjen, B.Sc.


Bioasis Announces Positive Results from Peripheral Whole-Body PET/CT Scan Study in Non-Human Primates with Lead Investigational Candidate xB3-001™
Posted on Tuesday November 20, 2018

OTCQB:BIOAF) (the “Company”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced data using the Company’s lead investigational candidate xB3-001 in an advanced positron emission tomography and computed tomography (PET/CT) imaging study in non-human primates suggest selective peripheral distribution. The data also indicates penetration of the lymphatic system with xB3-001.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.